EVP R&D, Chief Medical Officer
Mon, Nov 11, 2024
Nov 11
exercised or converted securities in ALKS
43,058 shares @ $20.03
Increased holdings by +43.40%
Net across this filing: -16.10% (-15,938 shares)
Option Exercise
Sale tied to a same-time option exercise